Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1997 Dec;35(12):3043–3047. doi: 10.1128/jcm.35.12.3043-3047.1997

Immunoblot analysis of Leishmania panamensis antigens in sera of patients with American cutaneous leishmaniasis.

D M Isaza 1, M Restrepo 1, W Mosca 1
PMCID: PMC230119  PMID: 9399491

Abstract

Sera from 86 Colombian patients with parasitologically confirmed cutaneous leishmaniasis were studied by immunoblot analysis in order to identify a specific pattern for Leishmania infection. A soluble extract of Leishmania panamensis was used as the antigen. Sera from patients with Chagas' disease and sera from patients with no record of infection with trypanosomatids were also studied. The sera from patients with cutaneous leishmaniasis specifically recognized fractions of 120 kDa (76.7%), 123 and 129 kDa (69.7%), 138 kDa (61.6%), 141 kDa (53.4%), and 78 kDa (44.1%). No band common to all patients infected with Leishmania parasites was found at the time of diagnosis. Likewise, the pattern of immunoblot change after the patients were treated and apparently cured with meglumine antimoniate (Glucantime) was studied by evaluating sera pretreatment and 1 year posttreatment. Only minor changes in the color intensity at the same serum dilution between pre- and posttreatment sera were found, although the antibody titers by indirect immunofluorescence were negative for the posttreatment sample. This study shows that Western blot analysis is a more sensitive test for the detection of anti-Leishmania antibodies. However, the importance of whether the presence of antibodies correlates with the presence of Leishmania antigens could not be resolved by the data obtained from this study.

Full Text

The Full Text of this article is available as a PDF (259.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvar J. Leishmaniasis and AIDS co-infection: the Spanish example. Parasitol Today. 1994 Apr;10(4):160–163. doi: 10.1016/0169-4758(94)90270-4. [DOI] [PubMed] [Google Scholar]
  2. Beverley S. M., Ismach R. B., Pratt D. M. Evolution of the genus Leishmania as revealed by comparisons of nuclear DNA restriction fragment patterns. Proc Natl Acad Sci U S A. 1987 Jan;84(2):484–488. doi: 10.1073/pnas.84.2.484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bogdan C., Stosiek N., Fuchs H., Röllinghoff M., Solbach W. Detection of potentially diagnostic leishmanial antigens by western blot analysis of sera from patients with kala-azar or multilesional cutaneous leishmaniasis. J Infect Dis. 1990 Dec;162(6):1417–1418. doi: 10.1093/infdis/162.6.1417. [DOI] [PubMed] [Google Scholar]
  4. Chiller T. M., Samudio M. A., Zoulek G. IgG antibody reactivity with Trypanosoma cruzi and Leishmania antigens in sera of patients with Chagas' disease and leishmaniasis. Am J Trop Med Hyg. 1990 Dec;43(6):650–656. doi: 10.4269/ajtmh.1990.43.650. [DOI] [PubMed] [Google Scholar]
  5. Convit J., Ulrich M., Fernández C. T., Tapia F. J., Cáceres-Dittmar G., Castés M., Rondón A. J. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):444–448. doi: 10.1016/0035-9203(93)90030-t. [DOI] [PubMed] [Google Scholar]
  6. Evans T. G., Krug E. C., Wilson M. E., Vasconcelos A. W., de Alencar J. E., Pearson R. D. Evaluation of antibody responses in American visceral leishmaniasis by ELISA and immunoblot. Mem Inst Oswaldo Cruz. 1989 Apr-Jun;84(2):157–166. doi: 10.1590/s0074-02761989000200003. [DOI] [PubMed] [Google Scholar]
  7. Fernández-Guerrero M. L., Aguado J. M., Buzón L., Barros C., Montalbán C., Martín T., Bouza E. Visceral leishmaniasis in immunocompromised hosts. Am J Med. 1987 Dec;83(6):1098–1102. doi: 10.1016/0002-9343(87)90948-x. [DOI] [PubMed] [Google Scholar]
  8. Hoerauf A., Andrade P. P., Andrade C. R., Solbach W., Röllinghoff M. Immunoblotting as a valuable tool to differentiate human visceral leishmaniasis from lymphoproliferative disorders and other clinically similar diseases. Res Immunol. 1992 May;143(4):375–383. doi: 10.1016/s0923-2494(05)80070-7. [DOI] [PubMed] [Google Scholar]
  9. Jaffe C. L., Shor R., Trau H., Passwell J. H. Parasite antigens recognized by patients with cutaneous leishmaniasis. Clin Exp Immunol. 1990 Apr;80(1):77–82. doi: 10.1111/j.1365-2249.1990.tb06444.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jaffe C. L., Zalis M. Purification of two Leishmania donovani membrane proteins recognized by sera from patients with visceral leishmaniasis. Mol Biochem Parasitol. 1988 Jan 1;27(1):53–62. doi: 10.1016/0166-6851(88)90024-2. [DOI] [PubMed] [Google Scholar]
  11. Kar K. Serodiagnosis of leishmaniasis. Crit Rev Microbiol. 1995;21(2):123–152. doi: 10.3109/10408419509113537. [DOI] [PubMed] [Google Scholar]
  12. Malchiodi E. L., Chiaramonte M. G., Taranto N. J., Zwirner N. W., Margni R. A. Cross-reactivity studies and differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp; use of immunoblotting and ELISA with a purified antigen (Ag163B6). Clin Exp Immunol. 1994 Sep;97(3):417–423. doi: 10.1111/j.1365-2249.1994.tb06104.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Marty P., Lelièvre A., Quaranta J. F., Suffia I., Eulalio M., Gari-Toussaint M., Le Fichoux Y., Kubar J. Detection by Western blot of four antigens characterizing acute clinical leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):690–691. doi: 10.1016/0035-9203(95)90447-6. [DOI] [PubMed] [Google Scholar]
  14. Mary C., Lamouroux D., Dunan S., Quilici M. Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes. Am J Trop Med Hyg. 1992 Dec;47(6):764–771. doi: 10.4269/ajtmh.1992.47.764. [DOI] [PubMed] [Google Scholar]
  15. Reed S. G., Badaro R., Lloyd R. M. Identification of specific and cross-reactive antigens of Leishmania donovani chagasi by human infection sera. J Immunol. 1987 Mar 1;138(5):1596–1601. [PubMed] [Google Scholar]
  16. Reiner S. L., Locksley R. M. Lessons from Leishmania: a model for investigations of CD4+ subset differentiation. Infect Agents Dis. 1992 Feb;1(1):33–42. [PubMed] [Google Scholar]
  17. Rolland-Burger L., Rolland X., Grieve C. W., Monjour L. Immunoblot analysis of the humoral immune response to Leishmania donovani infantum polypeptides in human visceral leishmaniasis. J Clin Microbiol. 1991 Jul;29(7):1429–1435. doi: 10.1128/jcm.29.7.1429-1435.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rolland L., Zilberfarb V., Furtado A., Gentilini M. Identification of a 94-kilodalton antigen on Leishmania promastigote forms and its specific recognition in human and canine visceral leishmaniasis. Parasite Immunol. 1994 Nov;16(11):599–608. doi: 10.1111/j.1365-3024.1994.tb00316.x. [DOI] [PubMed] [Google Scholar]
  19. Tapia F. J., Cáceres-Dittmar G., Sánchez M. A. Inadequate epidermal homing leads to tissue damage in human cutaneous leishmaniasis. Immunol Today. 1994 Apr;15(4):160–165. doi: 10.1016/0167-5699(94)90312-3. [DOI] [PubMed] [Google Scholar]
  20. de Rossell R. A., de Duran R. J., Rossell O., Rodríguez A. M. Is leishmaniasis ever cured? Trans R Soc Trop Med Hyg. 1992 May-Jun;86(3):251–253. doi: 10.1016/0035-9203(92)90297-p. [DOI] [PubMed] [Google Scholar]
  21. dos Santos J. I., Morgado M. G., Galvão-Castro B. Human visceral leishmaniasis: analysis of the specificity of humoral immune response to polypeptides of Leishmania donovani chagasi. Am J Trop Med Hyg. 1987 Sep;37(2):263–270. doi: 10.4269/ajtmh.1987.37.263. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES